Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mercadolibre Inc (MELI) vs 10X Genomics Inc (TXG) Price & Performance

Mercadolibre IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Mercadolibre Inc vs 10X Genomics Inc — how do they compare? Mercadolibre Inc trades at $1,883.54 (market cap $98.35B), while 10X Genomics Inc trades at $59.15 (market cap $7.61B). The key difference: Mercadolibre Inc is far larger — about 12.9× 10X Genomics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals.

MELITXG
Market Cap
$98.35B$7.61B
Sector
Consumer CyclicalHealth
52-Week High
$2.51K$58.57
52-Week Low
$1.55K$11.34
Enterprise Value
$106.00B$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mercadolibre Inc

MercadoLibre (MELI) trades at $1,824.34, up 0.2% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $9.19, beating estimates by 6.2%, while revenue grew 50% year-over-year. Operating cash flow reached $12.12 billion in 2025, supporting aggressive growth investments. Analyst consensus remains strongly bullish with a $2,150 price target, though margin compression from strategic spending presents near-term headwinds.

MELI's growth-first strategy drives market share gains but pressures profitability, with net margin declining to 5.3%. The stock offers 18% upside to consensus target but faces execution risk in balancing expansion with returns. Competitive threats from global e-commerce players and Latin American economic volatility require monitoring. Long-term prospects remain positive given ecosystem strength and dominant market position.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mercadolibre Inc

MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.

Read more on MELI

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG